General Motors Company vs Smith & Nephew plc — how do they compare? General Motors Company trades at $82.38 (market cap $72.17B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: General Motors Company is far larger — about 6.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Smith & Nephew plc for 120 Days on average.
| GM | SNN | |
|---|---|---|
Market Cap | $72.17B | $11.10B |
Volume | 4,900,304 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $37.17 |
52-Week Low | $55.35 | $26.42 |
Typical Hold Time | 83 Days | 120 Days |
Enterprise Value | $175.15B | $14.13B |
Dividend Yield | 0.88% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $80.99, down 1.24% amid broader auto sector weakness. The stock shows mixed signals with bearish technical indicators but strong analyst support (66.7% buy rating) and a $102.08 consensus price target. Recent Q3 2026 sales declined 5.5% due to EV weakness and discontinued models, though the company has beaten earnings estimates for three consecutive quarters. GM benefits from regulatory savings of $20.4B through 2031 from eased fuel economy rules.
GM faces near-term headwinds from declining vehicle sales and competitive pressure from Asian automakers, but maintains solid cash flow and attractive valuation metrics (P/S 0.42). The stock offers 26% upside to analyst targets, though profitability compression and market share losses present ongoing challenges for investors.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →